Harbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical to develop and commercialise HBM7020, a BCMAxCD3 bispecific T-cell engager, for the treatment of autoimmune diseases.

和铂医药与大冢制药达成全球战略合作，开发并商业化用于治疗自身免疫性疾病的BCMAxCD3双特异性T细胞衔接器HBM7020。

HBM7020 is engineered to connect B cell maturation antigen (BCMA) on target cells and CD3 on T cells, triggering T cell activation and the targeted destruction of disease-associated cells. The bispecific antibody uses dual anti-BCMA binding for enhanced targeting and a single CD3 binding domain to help reduce cytokine release syndrome.

HBM7020 被设计用于连接靶细胞上的B细胞成熟抗原（BCMA）和T细胞上的CD3，触发T细胞活化并针对性地摧毁与疾病相关的细胞。该双特异性抗体利用双重抗BCMA结合以增强靶向性，并使用单一的CD3结合域以帮助减少细胞因子释放综合征。

It has shown strong potential in preclinical studies for both immune-related and cancer indications..

它在免疫相关和癌症适应症的临床前研究中显示出强大的潜力。

Under the agreement, Otsuka will hold exclusive rights to develop, manufacture, and commercialise the therapy outside Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan. Harbour BioMed will receive $47 million in upfront and near-term payments, with the potential to earn up to $623 million in milestone-based payments, in addition to tiered royalties on future net sales..

根据协议，大中华区（包括中国大陆、香港、澳门和台湾）以外，大冢将拥有该疗法的独家开发、生产和商业化权利。和铂医药将获得4700万美元的预付款和近期付款，此外还有可能获得高达6.23亿美元的基于里程碑的付款，以及未来净销售额的分级特许权使用费。

Otsuka plans to incorporate HBM7020 into its expanding pipeline of autoimmune disease treatments, supported by the technology platforms of its subsidiaries, Visterra and Jnana.

大冢计划在其不断扩展的自身免疫疾病治疗管道中纳入HBM7020，该计划将得到其子公司Visterra和Jnana的技术平台支持。

The therapeutic candidate is expected to be effective across a range of autoimmune conditions where B cells play a key role.

该治疗候选药物预计将在一系列B细胞起关键作用的自身免疫疾病中有效。

This collaboration strengthens Harbour BioMed’s position in the T-cell engager space and supports the use of its proprietary Harbour Mice® and HBICE® platforms, which are designed to develop fully human bispecific antibodies with improved safety and efficacy.

此次合作加强了和铂医药在T细胞衔接器领域的地位，并支持其使用专有的Harbour Mice®和HBICE®平台，这些平台旨在开发具有更高安全性和有效性的全人源双特异性抗体。

Source: harbourbiomed.com

来源：harbourbiomed.com